| Форма представления | Статьи в зарубежных журналах и сборниках |
| Год публикации | 2015 |
| Язык | английский |
|
Зиганшина Лилия Евгеньевна, автор
|
| Библиографическое описание на языке оригинала |
DOI 10.3233/JRS-150657
Ziganshina, L.E. Book reviews.The Price of Global Health: drug strategies to balance patient acces and the funding of innovation/ Ziganshina, L.E.// International Journal of Risk & Safety in Medicine- 2015. - 27(3). - Р.159-165.
|
| Аннотация |
International Journal of Risk & Safety in Medicine |
| Ключевые слова |
drug pricing, price, cost, medicines, global health, disease burden |
| Название журнала |
International Journal of Risk & Safety in Medicine
|
| URL |
http://content.iospress.com/articles/international-journal-of-risk-and-safety-in-medicine/jrs657 |
| Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на эту карточку |
https://repository.kpfu.ru/?p_id=125076 |
| Файлы ресурса | |
|
|
Полная запись метаданных  |
| Поле DC |
Значение |
Язык |
| dc.contributor.author |
Зиганшина Лилия Евгеньевна |
ru_RU |
| dc.date.accessioned |
2015-01-01T00:00:00Z |
ru_RU |
| dc.date.available |
2015-01-01T00:00:00Z |
ru_RU |
| dc.date.issued |
2015 |
ru_RU |
| dc.identifier.citation |
DOI 10.3233/JRS-150657
Ziganshina, L.E. Book reviews.The Price of Global Health: drug strategies to balance patient acces and the funding of innovation/ Ziganshina, L.E.// International Journal of Risk & Safety in Medicine- 2015. - 27(3). - Р.159-165.
|
ru_RU |
| dc.identifier.uri |
https://repository.kpfu.ru/?p_id=125076 |
ru_RU |
| dc.description.abstract |
International Journal of Risk & Safety in Medicine |
ru_RU |
| dc.description.abstract |
International Journal of Risk & Safety in Medicine |
ru_RU |
| dc.description.abstract |
The book creates an impression of a textbook or guideline of marketing practices for pharmaceutical company managers. The author states under the heading of industry cost structure ?the cost of development
of a new drug was estimated to be in excess ofc $ 1.3 billion in 2006 (DiMasi, 2007) [6]. Given the past steep growth curve in the cost of drug development, today ?s average cost of drug development is probably
much higher than $ 1.3 billion dollars.?
This is the first in ten industry myths, described and debunked by Professor Peter C. Gøtzsche,
the Director of the Nordic Cochrane Centre and the co-founder of the Cochrane Collaboration in
his ground-breaking book ?Deadly Medicines and Organised Crime. How big pharma has corrupted healthcare? [7].
|
ru_RU |
| dc.language.iso |
ru |
ru_RU |
| dc.subject |
drug pricing |
ru_RU |
| dc.subject |
price |
ru_RU |
| dc.subject |
cost |
ru_RU |
| dc.subject |
medicines |
ru_RU |
| dc.subject |
global health |
ru_RU |
| dc.subject |
disease burden |
ru_RU |
| dc.title |
Book reviews.The Price of Global Health: drug strategies to balance patient acces and the funding of innovation |
ru_RU |
| dc.type |
Статьи в зарубежных журналах и сборниках |
ru_RU |
|
EN 
中文 
ES 
Карта сайта
